All News
RheumNow Live is Coming to Town (3.11.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Read Article
Retrospective cohort study of 338 pregnancies in IMID pts (~1/2 w/ IBD); 23% w/ biologic exposure had increase in post-partum flares (OR 3.44) & less being breastfeed (OR 0.44). Maternal and neonatal pregnancy outcomes were similar https://t.co/8pu2p8tK0s https://t.co/bVQx9La5j3
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean study (TB endemic area) shows the risk of mTB & nontuberculous mycobact infx (NTM) are equal and nearly doubled in RA pts on TNFi. Among 4356 RA (1089 on TNFi) NTM & TB rates were 328- and 341/100K PY (US rate is 6/100K PY) https://t.co/QwzTYt3wX4 https://t.co/GLWreoQ6ih
Dr. John Cush RheumNow ( View Tweet)
ICYMI: CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/jM8UKwBp7u https://t.co/fOc8Ay8KU3
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available.
https://t.co/FBCQRu32gO
https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO
Dr. John Cush RheumNow ( View Tweet)
ICYMI: anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/6MQ3CMU7YG https://t.co/okl2e1Q6Hs
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundation
https://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA.
- Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality
- Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks
- Steroid sparing w/ MTX, AZA or TNFi https://t.co/Ue4V1uAhRF https://t.co/5ap3bPzoNk
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Undifferentiated Arthritis Does Not Follow an RA Course
UA is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach.
https://t.co/l0U4IVAXMG https://t.co/8YPM8DgX8H
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available. It kicks off one week from today!
https://t.co/mMlAC3OXTJ
https://t.co/DY32PxQnRm https://t.co/kcIQ2GdObr
Dr. John Cush RheumNow ( View Tweet)
The Differential on Tenosynovitis
70 yr old man with tenosynovitis - imagine the possibilities
QD Clinic is sponsored by https://t.co/4UQlqwujiR
(March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/HraAZHIKA9 https://t.co/nzG6tlXuJU
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa
Links:
Dr. John Cush RheumNow ( View Tweet)
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 177 PsA pts, those with dactylitis had more severe disease with signif. greater SJC, CRP, US-detected synovitis and bone erosions in DMARD-naive early PsA. Dactylitis could be useful in early risk stratification. https://t.co/zUoWSEFxaN
Links:
Dr. John Cush RheumNow ( View Tweet)
6780 nonspecific MSK pts (no synovitis) saw 3% w/ CCP+, 45% progressed to IA (RA). Progression seen w/ high CCP (OR 9.4), hand (OR 2.7) & foot pain (OR 4.1). CCP- progress if pain in hands (OR 2.5) or knees. 96% NPV for CCP- w/o hand/foot pain https://t.co/FbDIggQFLJ https://t.co/VtvRUOHTnc
Links:
Dr. John Cush RheumNow ( View Tweet)
What To Do With the NSAID?
Elderly arthritis needs something for pain - what to do with the NSAID?
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/YmGTOVJymm https://t.co/T3Y8LUNHVk
Dr. John Cush RheumNow ( View Tweet)
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS
Links:
Dr. John Cush RheumNow ( View Tweet)
CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/nXEBMuSDZL https://t.co/fa9yOqtxiI
Links:
Dr. John Cush RheumNow ( View Tweet)